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Although (S)-ketamine was approved for use in treatment-resistant depression in 2019,
new preclinical ndings suggest that (R)-ketamine might produce better ecacy and
tolerability relative to (S)-ketamine. Here we evaluated the eects of (R)-, (S)-, and (R,S)-
ketamine on executive functions as measured in the attentional set shiing task (ASST)
and on their discriminative stimulus eects in rats. Earlier data demonstrated that cog-
nitive exibility is compromised by (R,S)-ketamine, but the eects of enantiomers in
rats are unknown. Separate cohorts of rats were tested in ASST and trained to dis-
criminate either (R,S)-ketamine, (S)-ketamine, or (R)-ketamine (all at 10 mg/kg) from
saline; in order tomaintain the discrimination, a higher (R)-ketamine dose (17.5 mg/kg)
was subsequently instituted. In ASST, all three forms increased the trials to criterion
measure at reversal learning and extra-dimensional set-shiing phases. However, in
contrast to (R)- and (S)-ketamine, (R,S)-ketamine prolonged the mean time to complete
a single trial during early stages, suggesting increased reaction time, and/or unspe-
cic side-eects related to motor or motivational impairments. In the drug discrimi-
nations, all rats acquired their respective discriminations between drug and saline. In
(R,S)-ketamine-trained rats, (R)-ketamine and (S)-ketamine only partially substituted
for the training dose of (R,S)-ketamine. Further, (R)-ketamine did not fully substitute in
rats trained to (S)-ketamine. The data suggest more serious cognitive decits produced
by (R,S)-ketamine than its enantiomers. Furthermore, (R,S)-ketamine and its isomers
share overlappingbut not isomorphic discriminative stimulus eects predicting distinct
subjective responses to (R)- vs. (S)-ketamine in humans.
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1. Introduction
Ketamine, a structural analog of phencyclidine (PCP), was rst synthesized in 1962
under the name CI-581 by Calvin Stevens (see historical overview by Mion (2017)). Just
a few years later, ketamine was reported to be a general anesthetic in animals and
studied in humans by Domino et al. (1965) who termed ketamine a dissociative anes-
thetic. Some 40 years aer its synthesis, data on eects of ketamine in patients with
major depressive disorder began a revolution in the eld of neuropsychiatry. Zarate
et al. (2006) from the U.S. National Institutes of Health reported that a 40 min infusion
with ketamine at a sub-anesthetic dose was able to produce immediate response in
patients suering from treatment-resistant depression. These eects were prefaced by
thework of Berman et al. (2000) in depressed patients and by the preclinical predictions
of ecacy of ketamine in depression by Trullas and Skolnick (1990) 10 years earlier.
Twenty-three years earlier, the NMDA receptor antagonist actions of ketamine were
rst disclosed (Anis et al. 1983). The rapid onset of antidepressant eect, the ability to
impact treatment-refractory patients, and the relatively large eect size of ketamine’s
antidepressant eects immediately caught the attention of the scientic research and
patient communities.
In 2019, the (S)-isomer of ketamine (esketamine) was approved for use in treatment-
resistant depression in the United States (Spravato) and in Europe (Cristea & Naudet
2019). Ketamine also has potential as a therapeutic agent for pain (Nielsen et al. 2019;
Persson et al. 1998), substance abuse disorder (Dakwar et al. 2020; Jones et al. 2018;
Witkin et al. 2020), and other psychiatric disorders such as obsessive- compulsive dis-
order and anxiety disorders (Banov et al. 2019) as well as post-traumatic stress disorder
(Liriano et al. 2019). The promise of ketamine as a medicine is tempered by safety, tol-
erability, and side-eect issues. Ketamine produces psychotomimetic and dissociative
eects and can produce anxiety and dysphoria (Nugent et al. 2019). Ketamine is also
a drug with high abuse potential (Ji Kwon & Han 2019). Of particular importance are
ketamine-induced cognitive disturbances in humans that are expressed as impaired
performance on tests of vigilance, verbal uency, and the Wisconsin Card Sorting Test,
indicating frontal cortical dysfunction (Krystal et al. 1994).
These pharmacological eects of racemic ketamine have led researchers to look for a
‘milder andgentler ketamine’with comparable ecacy. This searchhas gone in ahost of
directions and led to several potential lead molecules and mechanisms (c.f. Hashimoto
2019; Witkin et al. 2019, 2020). Although S(+)-ketamine was the isomeric form approved
as a medicine for depression, accumulating data have recently suggested that R(—)-
ketamine might be superior for patients. In preclinical studies, (R)-ketamine is more
potent and longerlasting than (S)-ketamine in its antidepressant-like eects in rodents
(Chang et al. 2019; Fukumoto et al. 2017; Zhang et al. 2014). Rodent data also point to the
possibility that (R)-ketaminemight be an improvement over (S)-ketamine in tolerability
and safety. In these studies (R)-ketamine produced less psychotomimetic eects and
abuse liability than (S)-ketamine (Chang et al. 2019; Yang et al. 2015, see also Zanos et al.
2018).
Neuroimaging studies in nonhuman primates have suggested a basis for these behav-
ioral observations. (S)-ketamine but not (R)-ketamine increased dopamine release in
the striatum, a neurochemical phenomenon associated with psychotomimetic eects
(Hashimoto et al. 2017). (S)- but not (R)-ketamine produced anhedonia-like eects in
rats that electrically self-stimulated the medial forebrain bundle (Witkin et al. 2020).
Data from the few studies evaluating (R)-ketamine inhumanshave also indicatedmilder
eects of the (R)-isomer. Persson et al. (2002) reported that (R)-ketamine induced less
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subjective reports than (S)-ketamine (drunk, dream-like, oating, distorted experience).
And, one study showed qualitative dierences in reactions to ketamine isomers in hu-
mans. In a study by Vollenweider et al. (1997), (S)-ketamine produced psychotic-like
eects whereas comparable doses of (R)-ketamine produced calmness. A more recent
study conrmed the prediction that (R)-ketamine would be antidepressant at doses en-
gendering a relatively benign side-eect prole. A small (n = 7) open label study showed
ecacy of (R)-ketamine infusion in treatment-resistant depressed patients without in-
ducing dissociative-like eects (Leal et al. 2020). Interestingly, all patients reported the
sensations of serenity and inner peace with (R)-ketamine (Leal et al. 2020).
Given the rodent and human data that align to show that (R)-ketaminemight produce
quantitatively and qualitatively distinct pharmacological eects, we asked the ques-
tion as to whether (R,S)-, (R)- and (S)- ketamine might produce distinct cognitive im-
pairments and discriminative stimulus eects in rats. To measure cognitive eects of
ketamines we used the attentional set shiing task (ASST), based on the human test
analog, the Wisconsin Card Sorting Test, that assesses cognitive exibility, that is, the
ability to modify behavior in response to changes in the relevance of discriminative
stimuli. In this paradigm, rats must select a bowl containing a food reward based on
the ability to discriminate the odors or the media covering the food (Birrell & Brown
2000). TheASST requires rats to initially learn a rule and forman attentional “set”within
the same stimulus dimensions. At the extradimensional (ED) shi stage, animals must
switch their attention to a previously irrelevant stimulus dimension (e.g., discriminate
between the odors and not between the media). The animal’s performance at the ED
stage is considered an index of cognitive exibility. Ketamine-induced cognitive inex-
ibility observed in humans (Krystal et al. 1994) and in the ASST in rats (Nikiforuk et al.
2010; Potasiewicz et al. 2019), suggests high translational value of this test. However,
the dierences in cognitive eects of racemic ketamine and its enantiomers have not
been examined in rodents. In the present study we directly compared the cognitive
impairment produced by (R,S)-, (R)- and (S)-ketamine using the ASST.
In drug discrimination studies, rats are trained to report the presence of a drug vs. its
absence. The ability of another drug to substitute for the training drug has been used as
a valid predictor of the subjective eects of drugs in humans (Holtzman 1985; Schuster
& Johanson 1988). For example, Balster & Willets (1988) showed that uncompetitive
NMDA receptor antagonists produce a common discriminative stimulus eect in rats
as they produce similar subjective reports in humans. Drug discrimination studies are
one of the tests oen required by the U.S. Food and Drug Administration (FDA) and the
Drug Enforcement Agency (DEA) in assessing abuse liability and this assay is validated
for ketamine-like drugs (Klein et al. 1999). Moreover, these methods are adaptable to
humans (Bolin et al. 2016; Schuster & Johanson 1988). Given the utility of drug dis-
crimination data, these studies have been used to identify compounds with reduced
liabilities for engendering specic subjective eects in humans. For example, the idea
that glycine-site antagonists of NMDA receptors might not produce PCP-like subjective
responses was studied in rats trained to discriminate PCP from drug vehicle (Witkin
et al. 1997). Drug discrimination data constituted the basis for the bet that GLYX-13
would not produce subjective eects like that of PCP (Burgdorf et al. 2013), a prediction
born out in antidepressant trials in patients (Preskorn et al. 2015). Here, we trained
separate groups of rats to discriminate (R,S)-ketamine from vehicle, (S)-ketamine from
vehicle, or (R)-ketamine from vehicle. Aer training, when the rats had achieved>85%
accuracy in selecting the drug- from the vehicle-associated response alternative, we
substituted the other isomeric drug forms. Based upon the dierential eects of these
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drug forms summarized above, we predicted that (R)- and (S)- ketamine would display
distinct discriminative stimulus eects.
2. Methods
2.1. Animals and ethics
Thirty (ASST) and 23 (drug discrimination) male Sprague–Dawley rats (Charles River,
Germany) weighing 250 g upon arrival were group housed (5 per cage) in standard
laboratory cages, under standard colony controlled conditions: room temperature 21
± 2 °C, humidity (40–50%), 12-hr light/dark cycle (lights on: 06:00) with ad libitum access
to water and with a mild food restriction for at least one week prior to training. Rats
were allowed to acclimatize for at least 7 days before the start of the experimental
procedure; during this time the animals were frequently handled. At least 1 h before
the start of experimental procedures, rats were transferred to the experimental room
for acclimation.
In both studies, 17 g per day per animal of standard laboratory chowwas provided 1 h
aer the training or testing sessions, i.e., at 13:00. The animals were group-fed in their
home cages. Onmost of theweekend days no sessions were conducted, and the animals
were given the same amount of 17 g/rat of food starting at 13:00. All animals were main-
tained, and experiments were conducted in accordance with the European Guidelines
for animal welfare (2010/63/EU) and all experimental procedures were approved by the
II Local Ethics Committee forAnimal Experiments at theMaj Institute of Pharmacology,
Polish Academy of Science, Krakow, Poland. None of the rats had previously received
drugs or behavioral training.
2.2. Drugs
(R,S)-ketamine (115.34 mg/ml of an aqueous solution, Vetoquinol Biowet, Gorzow
Wielkopolski, Poland), (R)-ketamine HCl (Seqens, Germany), and (S)-ketamine HCl
(Celon Pharma, Warsaw, Poland) were dissolved in sterile water on the day of training
or testing. Sterile 0.9% physiological saline served as the control solution.
2.2.1. Chemistry
To ensure that the enantiomeric forms of ketamine used in the present study were
the forms as stated, we employed analytical methods. Optical rotation measurements
of ketamine hydrochlorides were carried out in water using a Jasco P-2000 polarimeter
(Tokyo, Japan). Next, the aqueous ketamine HCl solution was basied with 10% NaOH
solution and the free amine was extracted with diethyl ether. The organic phase was
dried over anhydrous Na2SO4, ltered, concentrated in vacuo to dryness and submitted
for enantiomeric excess determination with HPLC. HPLC analyses were performed
on a Jasco HPLC system (Tokyo, Japan) equipped with a Daicel column with a chiral
stationary phase (CHIRALCEL OD-H) and a UV detector (detection at 254 nm).
2.2.2. ASST study
The cognitive eects of (R,S)-ketamine (10 mg/kg, SC, given 1 h before the test) were
reported by our laboratory (Nikiforuk et al. 2010; Potasiewicz et al. 2019). Therefore, in
the present study we used the racemate and ketamine enantiomers at the same doses
of 10 mg/kg.
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2.2.3. Drug discrimination study
Injections were given intraperitoneally (IP), 15 min before training and testing in a
volume of 1 ml/kg. The choice of doses and of the time between drug administration
and the experimental session was based on earlier work (Chiamulera et al. 2016; Kos
et al. 2006). Initially, all ketamines were administered at the dose of 10mg/kg. However,
we observed similar eects as in the De Vry & Jentzsch (2003) study who started the
drug discrimination experiment with 5 mg/kg of ketamine, and due to the diculty
in reaching stable discrimination performance within the rst 40 sessions, raised the
training dose to 7.5 mg/kg. Our 10 mg/kg (R)-ketamine trained rats also had diculty in
reaching stable discrimination performance within the rst 50 sessions, and therefore
we increased the training dose from the starting dose of 10 mg/kg to 17.5 mg/kg of (R)-
ketamine. (R)-ketamine animals received this dose to the end of the study.While we are
aware that this creates diculty with comparisons across groups due to the dierence
in training dose (10 mg/kg of (R,S)- and (S)-ketamine vs. 17.5 mg/kg of (R)-ketamine),
the dose escalation of ¼ log unit was necessary for behavioral control. Thus, the nal
doses used to maintain the drug discriminations were 10 mg/kg for (R,S)-ketamine and
for (S)-ketamine and 17.5 mg/kg for (R)-ketamine.
2.3. ASST
2.3.1. Apparatus
Testing was conducted in a dimly illuminated (20 Lux) Plexiglas apparatus (length ×
width × height: 38 × 38 × 17 cm) with the grid oor and wall dividing half of the length of
the cage into two sections. During testing, one ceramic digging pot (internal diameter
of 10.5 cm and a depth of 4 cm) was placed in each section. Each pot was dened by
a pair of stimulus cues with two stimulus dimensions (odor and digging medium). To
mark each pot with a distinct odor, 5 µl of a avoring essence (Dr. Oetker®, Poland or
The Body Shop, UK) was applied to a piece of blotting paper xed to the external rim
of the pot immediately prior to use. A dierent pot was used for each combination of
digging medium and odor; only one odor was ever applied to a given pot. The bait (one-
half of a Honey Nut Cheerio, Nestle®) was placed at the bottom of the “positive” pot and
buried in the digging medium. A small amount of powdered Cheerio was added to the
digging media to prevent the rat from trying to detect the buried reward by its smell.
2.3.2. Procedure
As described previously (e.g. Potasiewicz et al. 2019), the procedure was conducted
over a period of three consecutive days for each rat.
Day 1, habituation: rats were habituated to the testing area and trained to dig in the
pots lled with sawdust to retrieve the food reward. The rats were transported from the
housing facility to the testing room where they were presented with one unscented pot
(lled with several pieces of Cheerios) in their home cages. Aer the rats had eaten the
Cheerio from thehomecagepot, theywereplaced in the apparatus andgiven three trials
to retrieve the reward from both of the sawdust-lled baited pots. With each exposure,
the bait was covered with an increasing amount of sawdust. Animals that did not dig for
a food reward over 3 consecutive daily sessions were excluded from the experiment.
Day 2, training: rats were trained on a series of simple discriminations (SDs) to a
criterion of six consecutive correct trials. For these trials, the rats had to learn to as-
sociate the food reward with an odor cue (e.g., arrack vs. orange, both pots lled with
sawdust) and/or a diggingmedium (e.g., plastic balls vs. pebbles, no odor). All rats were
trained using the same pairs of stimuli. The positive and negative cues for each rat were
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presented pseudo-randomly and equally. These training stimuli were not used again in
later testing trials.
Day 3, testing: rats performed a series of discriminations in a single test session. The
rst four trials at the beginning of each discrimination phase were discovery trials, dur-
ing which the animals were allowed to dig in both bowls. The rst trial of the discovery
period was not included in the six criterion trials. In the subsequent trials, each incor-
rect choice was recorded as an error. Digging was dened as any distinct displacement
of the digging media with either the paw or the nose; the rat could investigate a digging
pot by sning or touching without displacing material. Testing was continued at each
phase until the rat reached the criterion of six consecutive correct trials, aer which
testing proceeded to the next phase.
In the simple discrimination involving only one stimulus dimension, the pots diered
along one of two dimensions (e.g., digging medium). For the compound discrimina-
tion (CD), the second (irrelevant) dimension (i.e., odor) was introduced, but the cor-
rect and incorrect exemplars of the relevant dimension remained constant. For the
reversal of this discrimination (Rev 1), the exemplars and the relevant dimension were
unchanged, but the previously correct exemplar was now incorrect, and vice versa. The
intra-dimensional (ID) shi was then presented, comprising new exemplars of both the
relevant and irrelevant dimensions, with the relevant dimension remaining the same
as previously described. The ID discrimination was then reversed (Rev 2) so that the
formerly positive exemplar became the negative one. For the extra-dimensional (ED)
shi, a new pair of exemplars was again introduced; however, this time, the relevant
dimension was also changed. Finally, the last phase was the reversal (Rev 3) of the ED
discrimination.
The following pairs of exemplars were used: Pair 1: odor: spicy vs. vanilla, medium:
cotton wool vs. crumpled tissue; Pair 2: odor: lemon vs. almond, medium: shredded
pipette tips vs. wooden sticks; and Pair 3: odor: rum vs. cream, medium: shredded
papers vs. silk. The exemplars were always presented in pairs, and they varied so that
only one animal within each treatment group received the same combination. The
assignment of each exemplar in a pair as being positive or negative at a given phase and
the le-right positioning of the pots in the test apparatus on each trial were randomized.
Each rat was tested nomore than twice, with at least a 7-day washout period between
each of the two tests. No animal received the same treatment twice. As our previous
study demonstrated the stability and reproducibility of the performance of rats during
repeated testing on the ASST (Potasiewicz et al. 2019), the repeated testing paradigmwas
used in the current experiments to reduce the number of animals used.
2.4. Drug discrimination
2.4.1. Apparatus
Six operant conditioning chambers (Med Associates, St Albans, VT, USA) measuring
56 cm × 56 cm × 40.5 cm were housed in soundattenuated and ventilated cubicles. Each
chamber was equipped with two nose-poke oparanda and a food magazine equipped
with photocell beam detectors and a light was located on the opposite wall. A house
light (5 W white bulb) was located 17 cm above the top edge of the food magazine. Food
pellets (45mg, BioserveDustless Precision Pellets, Frenchtown,NJ, USA)were delivered
via a dispenser connected to the food magazine. Online control of the apparatus and
data collection was performed using MED-PC soware (Med Associates). An exhaust
fan provided continuous masking noise. Following every session, the chambers were
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cleaned to avoid olfactory cues which may be deposited by animals and serve as dis-
crimination cues for other rats tested in the same chamber (Extance & Goudie 1981).
2.4.2. General procedure
2.4.2.1. Initial training. Animals were trained for 20 min to poke into either hole on a
xed-ratio 1 (FR1) reinforcement schedule in which each response produced food. Aer
the rats had acquired this behavior, they were trained for 20 min to poke on an FR1
schedule in one of the holes while poking into the other hole had no scheduled conse-
quences. When responding stabilized, training was shied to reinforcing responses in
the hole formerly non-reinforced. In this way, the rats were given discriminate training
on both nose holes.
2.4.3. Discrimination training
The drug discrimination procedure used was based on the classical work of Glennon
et al. (1983) and Gresch et al. (2007). Briey, the rats were trained every day at the
same time ( 09:00)Monday-Friday to discriminate a given form of ketamine from sterile
saline under a double alternating sequence, with at least two ketamine and two vehicle
sessions per week (e.g., K-K-V-V-K; Popik et al. 2019). Administration of ketamine or
saline 15 min prior to a variable interval 15 s (VI-15) schedule of reinforcement served
as the discriminative cue for the correct (reinforced) nose-poke.
Training sessions, during which correct responding was reinforced for the entire
20-min session, were interspaced with extinction sessions. Extinction sessions were
carried out twice per week at most, were always preceded with the training ketamine
or vehicle session and were used to assess the degree of stimulus control exerted by ke-
tamine or saline (Glennon et al. 1983). The extinction session consisted of a 2.5-min non-
reinforced test period, followed by “normal” 17.5-min training during which correct re-
sponses were reinforced (Stadler et al. 1999). To facilitate discrimination performance,
a 5-sec time-out aer incorrect respondingwas introduced duringwhich reinforcement
was withheld for responses on the correct hole.
2.4.3.1. Testing sessions. Once a stable level of performance was attained (>85% of
responses on the ketamine-appropriate hole aer administrationof ketamine and615%
of the total responses on the same hole aer administration of saline), generalization
studieswere conducted. These testing sessionswere carried out once aweek, usually on
Fridays or Saturdays andwere always preceded by the given ketamine or saline training
session. Rats were given generalization testing only if they met the stable response
criteria the day before. Doses were fully randomized for each rat. For every individual
generalization study, statistical comparison included specic data of the given ketamine
or saline training session preceding the test. Statistical comparisons of responding on
generalization tests were made by direct comparison to the preceding control session.
There were two dierences between the training and the testing session.While in the
training session (that lasted for 20min) the correct responseswere always reinforced, in
the testing session (2.5 min), responses into either hole were never reinforced. Testing
in the extinction conditions was done to prevent new discrimination learning (Colpaert
1987). Immediately aer the session was terminated, the rat was removed from the
testing chamber and placed in his home cage.
2.5. Study design
The cohort of 23 rats was randomly divided into three groups of animals that were
trained, following (R,S)-ketamine (N = 9), (R)-ketamine (N = 7) and (S)-ketamine (N =
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7) administration, to poke into one hole and, in another experimental session follow-
ing vehicle administration, to poke into the other hole. For approximately 50% of rats
the le hole was designated as the ketamine hole, and for the remaining animals, the




The number of trials required to achieve the criterion of six consecutive correct re-
sponses (i.e., trials to criterion, TTC) was recorded for each rat and for each discrim-
ination phase of the ASST. In addition, we analyzed the mean time taken to complete
every trial in a given SD, CD, Reversal 1, ID, Reversal 2, ED and Reversal 3 phases. Data
were analyzed using amixed design 2-way ANOVAwith treatment (Veh, (R,S)-, (R)-, (S)-)
as a between-subject factor and discrimination phase (SD, CD, Rev. 1, etc.) as a repeated
measure. As a post-hoc test, we used Newman-Keul’s test. Statistica 12 (Stat So, USA)
was used throughout.
2.6.2. Drug discrimination
Due to attrition of animals notmeeting response criteria for drug testing, the number
of data points for some experiments was low. In order for data to be included in statisti-
cal analyses, N values of 5—10 were required, with the exception of one data point with
N = 4 (the latter was embedded within a dose-response curve with total N of 27). To
estimate the dose of drug required to produce 50% drug responding (ED50) with 95%
condence limits, response accuracy data from vehicle and each drug dose tested were
log-transformed and tted using GraphPad Prism’s 7 sigmoidal dose-response equation:
Y = Bottom + (Top — Bottom) / (1 + 10ˆ((LogEC50 — X) ×HillSlope)). The criteria for drug
substitution used here were similar to those originally proposed by Colpaert (1987) and
by Fiorella et al. (1995) andwere determined by individual one-way ANOVAs followed by
Sidak’s post-hoc tests. Thus, the tested dose could engender a level of drug-appropriate
responding: a) signicantly dierent from that produced by vehicle condition and not
signicantly dierent from the drug (dened as full substitution), or, b) signicantly
dierent from that produced by drug and not signicantly dierent from the vehicle
training condition (dened as no substitution), or, c) signicantly dierent from both
vehicle and drug training conditions (dened as partial substitution).
Individual ANOVAs (GraphPad Prism’s 7) were also used to assess the eects of tested
compounds on the response rate, i.e., the number of nose-pokes recorded per 2.5-min
during extinction and testing sessions.
3. Results
3.1. Chemical purities of ketamines
Yokoyama et al. (2009) reported specic optical rotation for (S)-ketamine·HCl: [α]20D =
+91.7 (c 2.00,H2O). Our determinations display similar values for (S)-ketamine·HCl: [α]23D
= +93.2 (c 1.08, H2O), HPLC (free amine) ee > 99%, (Chiralcel OD-H, hexane/i-PrOH 95:5,
ow rate 0.5 ml/min, λ 254 nm): tR = 19.3 min (S), (racemate: tR = 16.7 min (R), tR = 19.6
min (S)). For (R)-ketamine·HCl, we observed the following values: [α]24D = —91.2 (c 0.72,
H2O); HPLC (free amine): ee > 99%, (Chiralcel OD-H, hexane/i-PrOH 95:5, ow rate 0.5
ml/min, λ 254 nm): tR = 16.7 min (R), (racemate: tR = 16.7 min (R), tR = 19.6 min (S)).
Overall, both specic rotations and HPLC analysis show that all of the ketamine forms
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FIGURE 1. Determination of enantiopurity of (R,S)-ketamine (Vetoquinol Biowet, Gorzow
Wielkopolski, Poland; top), (R)-ketamine (Seqens, Germany; middle), and (S)-ketamine (Celon
Pharma, Warsaw, Poland; bottom).
weused in this studywere optically purewith enantiomeric excess > 99%.No impurities
were found to be present in the samples. Fig. 1 shows chromatograms for the ketamine
forms studied.
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FIGURE 2. Eects of (R,S)- (R)- and (S)-ketamine, all at 10 mg/kg, SC, 1 h prior to testing, on trials
to criterion (TTC) in the attentional set shiing task (ASST) in rats. Data are presented as mean
± SEM. The number of rats tested was 7, 13, 13 and 13 for vehicle, (R,S)- (R)- and (S)-ketamine,
respectively. Symbols: * P < 0.05 vs. vehicle at a given phase, ˆP < 0.05 vs. vehicle’s ID phase.
FIGURE 3. Eects of (R,S)- (R)- and (S)-ketamine on time/measure in the attentional set shiing
task (ASST) in rats. Symbols: * P < 0.05 vs. vehicle at a given phase, # P < 0.05 vs. (R,S)-ketamine at
SD phase, ˆP < 0.05 vs. vehicle’s ID phase. Drug doses were 10 mg/kg, SC, 1 h prior to testing. For
other details, see the Legend to Fig. 2.
3.2. ASST
As shown on Fig. 2, both the specic treatment and the phase of the experiment af-
fected trials to criterion (TTC): F(18,252) = 1.857; P < 0.025. All 3 compounds increased the
TTCmeasure, particularly at the ED and Reversal 1 discrimination phase; (R)-ketamine
also increased TTC in the Reversal 2 discrimination (all P < 0.05).
Fig. 3 demonstrates that the specic treatment and phase of experiment also aected
the time/phase measure: F(18,252) = 2.016; P < 0.01. However, only (R,S)-ketamine pro-
longed the mean time to complete SD, Reversal 1 and ID phases (all P < 0.05).
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FIGURE 4. A. Dose-eect curve for (R,S)-ketamine in rats trained to discriminate (R,S)-ketamine
(10 mg/kg) from vehicle. Top panel: % drug-appropriate responses; bottom panel: response rate.
Dotted line represents 50% accuracy. Ns for (R,S)-ketamine at doses 0, 2.5, 5 and 10 mg/kg were
9, 4, 5 and 9, respectively. B. Eects of 17.5 mg/kg (R)-ketamine in rats trained to discriminate
(R)-ketamine (17.5 mg/kg) from vehicle. Top panel: % drug-appropriate responses; Bottom panel:
response rate. Ns for vehicle and for (R)-ketamine were 5. C. Eects of 10 mg/kg (S)-ketamine in
rats trained to discriminate (S)-ketamine (10 mg/kg) from vehicle. Top panel: % drug-appropriate
responses; Bottompanel: response rate.N for vehicle and for (S)-ketaminewere 6. Data are shown




Rats in the (R,S) and (S)-ketamine-trained groups acquired full discriminative control
by day 50. Since the (R)-ketamine discrimination was not maintained up to day 50, the
dose was increased to 17.5 mg/kg and this dose escalation re-invigorated discriminative
performances. At day 60, discrimination accuracy was sucient (>85%) to start substi-
tution testing. Nonetheless, at day 80 due to the insucient stimulus control (< 85% of
accuracy), we eliminated 2, 3, and 3 animals from (R,S)-, (R)- and (S)-ketamine groups,
respectively, and at day 102, an additional one animal from the (R)-ketamine group.
3.3.2. Discriminative control by (R)-, (S)-, and (R,S)-ketamine
Fig 4A shows the dose-response curve for (R,S)-ketamine in rats trained to discrimi-
nate (R,S)-ketamine (10 mg/kg) from vehicle. Oneway ANOVA documented a signicant
eect of (R,S)-ketamine dose: F(3,23) = 38.46; P < 0.05. As comparedwith vehicle, doses of
5 and 10 mg/kg resulted in higher (R,S)-ketamine-like hole responding; doses of 2.5 and
5mg/kg resulted in lower percentages than with the training dose of (R,S)-ketamine (10
mg/kg). For (R,S)-ketamine, the ED50 with 95% condence intervals was 4.19 (3.38–5.20)
mg/kg. (R,S)-ketamine doses also aected response rate: F(3,23) = 4.0; P < 0.05 and (R,S)-
ketamine at 2.5 mg/kg reduced response rates as compared to the training dose but not
as compared to its vehicle.
When the training dose of (R)-ketamine was tested in rats trained to discriminate (R)-
ketamine (17.5 mg/kg) from vehicle, full substitution of (R)-ketamine was achieved (t =
16; df = 8; P < 0.001; Fig. 4B top). Response rates were not signicantly dierent between
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FIGURE 5. In (R,S)-ketamine-trained rats, (R)-ketamine partially substituted for the training dose
of 10 mg/kg (R,S)-ketamine. N for vehicle, (R)-ketamine (17.5) and (R,S)-ketamine (10 mg/kg) was
9, 6 and 9, respectively. Symbols: *** P < 0.001 vs. vehicle, ### P < 0.001 vs. (R,S)-ketamine training
dose. Dotted lines represent 25 and 75% accuracy.
FIGURE 6. In (R,S)-ketamine-trained rats, (S)-ketamine partially substituted for the training dose
of 10 mg/kg (R,S)-ketamine. N for vehicle, (S)-ketamine (10 mg/kg) and (R,S)-ketamine (10 mg/kg)
was 10, 5 and 10, respectively. Symbols: *** P < 0.001 vs. vehicle, ### P < 0.001 vs. (R,S)-ketamine
training dose. Dotted lines represent 25 and 75% accuracy.
vehicle and (R)-ketamine (t = 0.51;df = 8;NS; Fig. 4Bbottom).Reduction in thenumberof
rats in the (R)-training group from attrition described above did not allow fully powered
data to evaluate dose-response relationships in this group.
When the training dose of (S)-ketamine was tested in rats trained to discriminate (S)-
ketamine (10 mg/kg) from vehicle, full substitution of (S)-ketamine was achieved (t =
14.56; df = 10; P < 0.001; Fig. 4C top). Response rates were not signicantly dierent
between vehicle and (R)-ketamine (t = 1.02; df = 10; NS; Fig. 4C bottom). Reduction in
the number of rats in the (S)-training group from attrition described above did not allow
fully-powered data to evaluate dose-response relationships in this group.
In all three groups of rats, when the training dose was tested, the variability in re-
sponding was very low, with all rats achieving high levels of discriminative control (Fig.
4).
3.3.3. Substitution of each isomeric form
In (R,S)-ketamine-trained rats, (R)-ketamine partially substituted for the training
dose of 10 mg/kg (R,S)-ketamine: F(2,21) = 110.0; P < 0.001. In this experiment (R)-
ketamine did not produce >75% drug-appropriate response in any of the 6 rats tested;
in contrast, none of the 9 rats tested with the training dose of (R,S)-ketamine exhibited
675% drug-appropriate responses. Response rates were not signicantly dierent from
one another in this experiment: F(2,21) = 2.715; P = 0.08 (Fig. 5). Partial substitution
occurred despite the fact that (R)-ketamine was given at dose exceeding the 5 mg/kg of
the (R)-enantiomer delivered by the 10 mg/kg (R,S)-ketamine training dose.
Similarly, (S)-ketamine also partially substituted for the training dose of (R,S)-
ketamine: F(2,22) = 128.8; P < .001. In this experiment (S)-ketamine produced >75%
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FIGURE 7. (R)-ketamine did not fully substitute for the training dose of (S)-ketamine in
(S)-ketamine-trained rats. Ns for vehicle and (S)-ketamine were 8, whereas 5 rats were tested with
(R)-ketamine (17.5 mg/kg). Symbols: * P < 0.05, *** P < 0.001 vs. vehicle, ### P < 0.001 vs. training
dose of (S)-ketamine. Dotted lines represent 25 and 75% accuracy.
drug-appropriate response only in one of the 5 rats tested; in contrast, only one of the 10
rats tested with the training dose of (R,S)-ketamine exhibited 675% drug-appropriate
responses. Response rates were not signicantly dierent from one another in this
experiment: F(2,22) = 2.33, NS (Fig. 6).
(R)-ketamine did not fully substitute for the training dose of (S)-ketamine in (S)-
ketamine-trained rats (Fig. 7): F(2,18) = 46.01; P < 0.001. Only 1 rat of the 5 tested showed
outlier responses of >75% (S)-ketamine-appropriate responses. In contrast, 0/8 rats
given 10 mg/kg (S)-ketamine demonstrated stimulus control 675%. There were no
signicant dierences in rates of responding produced by these compounds: F(2,18) =
0.41, NS (Fig. 7).
Partial substitution of (R)-ketamine occurred despite the fact that this enantiomer
was tested at the 17.5 mg/kg dose, exceeding those delivered by the 10 mg/kg of (R,S)-
ketamine (Fig. 5) and of (S)-ketamine (Fig. 7) training doses.
4. Discussion
Preclinical and clinical data have shown that there are quantitative and qualitative
dierences in the pharmacological eects of (R)- vs (S)-ketamine (summarized in the
Introduction). In line with our previously reported data (Nikiforuk et al. 2010), (R,S)-
ketamine disrupted rats’ ASST performance. Similar eects were demonstrated for (R)-
and (S)-ketamine in the present study, providing the rst report of the cognitive impact
of ketamine enantiomers in rodents. Specically, all compounds induced decits in
reversal learning and extra-dimensional set-shiing stages as measured by the trials
to criterion parameter. However, in contrast to (R)- and (S)-ketamine, (R,S)-ketamine
prolonged the time to complete a single trial during early stages of the ASST. This eect
may be interpreted as an increased reaction time, suggesting that the racemate may
have more detrimental eects on cognition than the individual enantiomers. In line
with these data, ketamine isomers induce less cognitive impairment than racemic ke-
tamine inhumanvolunteers (Pfenninger et al. 2002).Nevertheless, the increased time to
complete ASST stages aer (R,S)-ketaminemight also be interpreted as unspecic side-
eects related to motor or motivational impairments. Additional experiments will be
required to fully appreciate the behavioral mechanisms associated with the dierential
pharmacology reported here.
[t!]
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TABLE 1. Summary of the eects of dierent ketamine forms in rats trained to discriminate each
drug form from vehicle. NT: not tested due to insucient N.
Trained to Tested with
(R,S) 10 (R) 17.5 (S) 10
10 mg/kg of (R,S)-ketamine full partial partial Figure 4, 5 & 6
17.5 mg/kg of (R)-ketamine NT full NT Figure 4
10 mg/kg of (S)-ketamine NT partial full Figure 7
We used drug discriminationmethods in rats to further evaluate the potential for the
ketamine isomers to produce distinct subjective responses (see justication for drug
discriminationmethods for this purpose in the Introduction).We judged these potential
dierences by measuring the degree to which one isomer substituted for the others
(see Colpaert (1987)). In order to test the hypothesis that the enantiomers of ketamine
produce distinct subjective responses in humans as suggested by the literature (see In-
troduction), rats were trained to discriminate either 10 mg/kg (R,S)-ketamine, 10 mg/kg
(S)-ketamine, or 17.5 mg/kg (R)-ketamine from saline. Drug substitution tests, summa-
rized in Table 1, were conducted to ascertain the degree to which each isomer produced
comparable discriminative stimulus eect to that of the training dose.
Ketamine is a racemic mixture of equal parts (S)-ketamine and (R)-ketamine. There-
fore, in a discrimination based upon 10 mg/kg (R,S)-ketamine, this dose would be phar-
macologically equivalent to 5 mg/kg of each isomer. However, neither (R)- (Fig. 5) nor
(S)-ketamine (Fig. 6) fully substituted for the training dose of (R,S)-ketamine. The partial
substitution was found even though doses higher than 5mg/kg of each compound were
tested. Since drug substitutions under these conditions are dose-dependent (Balster &
Willets (1988); Brady & Balster (1982); Holtzman (1985); see also Fig. 4), then the test
for discriminative stimulus equivalence used here was a best-case scenario. However,
higher doses of each isomer (not tested here) might have substituted fully although the
interpretation of such a nding (given the 50% dose mixture of the racemate) would
require additional data to understand.
We are aware of only a few prior reports evaluating the question of whether the
isomers of ketamine produce similar or disparate discriminative stimulus eects. How-
ever, all studies utilized phencyclidine (PCP), not ketamine as a training drug. In these
studies, both (S)- and (R)- ketamine fully substituted for phencyclidine (PCP) (Brady &
Balster 1982; Zukin et al. 1984) as did the racemic mixture (Holtzman 1985) indicating
that the two isomers produce equivalent contributions to the discriminative stimulus
eects of PCP. In both reports, (R)-ketamine was about 2× less potent than (S)-ketamine
in producing discriminative stimulus eects comparable to PCP. These potency dier-
ences were also found in the present study although the lower potency of (R)-ketamine
in the current data set was biased somewhat by the higher training dose of (R)-ketamine
compared to that used for the (S)-ketamine drug discrimination (17.5 vs 10 mg/kg, re-
spectively).
That (R)-ketamine displayed unique discriminative stimulus eects in rats is further
demonstrated by the relatively diculty in maintaining the drug discrimination. Drug
discrimination at 10mg/kg, sucient for the racemate and for (S)-ketamine,wasnot suf-
cient to maintain discriminative performances in (R)-ketamine-trained rats. Increas-
ing the dose of (R)-ketamine to 17.5 mg/kg re-invigorated discriminative performances.
Nonetheless, the ability of (R)-ketamine to maintain accurate responding even at this
dose increase was not perfect. (R)-ketamine also was dierentiated from (S)-ketamine
in the rats trained to discriminate (S)-ketamine fromvehicle. In these rats, (R)-ketamine
did not display (S)-ketamine-like discriminative stimulus eects (Fig. 7, Table 1). Such
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ndings of subjective eect dierences in the ketamine enantiomers is mirrored in the
few clinical reports in which comparisons have been made (see Introduction).
It has been long thought that ketamine produces its primary pharmacological eects
through blockade of the NMDA receptor ion channel (Anis et al. 1983). Indeed, this
mechanism is generally consistent with ndings in the drug discrimination literature
where ketamine and PCP, for example, share common discriminative stimulus eects
(Brady & Balster 1982; Holtzman 1985; Zukin et al. 1984). Potency estimates of (R)- and
(S)-ketamine for the NMDA receptor ion channel (see Zanos et al. 2018, for a compre-
hensive review) have demonstrated that (S)-ketamine is about 4 timesmore potent than
(R)-ketamine (Ebert et al. 1997; Moaddel et al. 2013; Zukin et al. 1984). It is unlikely
that a potency dierence could account for the lack of full substitution reported in
this study or the lack of substitution of (R)-ketamine for (S)-ketamine reported here.
For example, memantine fully substitutes for the discriminative stimulus of the potent
NMDA receptor antagonist dizocilpine despite being 180-fold lower in potency (Geter-
Douglass & Witkin 1999). Nonetheless, a full test of the NMDA receptor hypothesis in
these drug discriminations would require additional scrutiny. In recent years, data have
accumulated to suggest alternatives to the NMDA receptor hypothesis (see Yang et al.
2019, and Zanos et al. 2019).
The present ndings demonstrate that the dierent isomeric forms of ketamine
produce overlapping but not identical mechanisms of action. Future research will be
needed to identify the underlying neurobiological substrates mediating the dierential
pharmacology observed. Results of this inquiry should lead to better control of patient
response and side-eect prole innext generationdrugs. The fact that (R)-ketaminewas
eective in treatment-resistant depressed patients, albeit in a small open-label study,
and produced very little in the way of dissociative eects (Leal et al. 2020) suggests
that one can create ecacy with reduced side-eects. Ketamine is a drug of abuse (see
Zanos et al. 2018) and drug discrimination commonalities suggest abuse potential (see
Klein et al. 1999; Schuster & Johanson 1988). The data from the present study showing
that (R)-ketamine does not fully substitute for (R,S) ketamine and also does not fully
substitute in rats discriminating (S)-ketamine provides some additional suggestion that
(R)-ketamine might have a reduced abuse liability. Such ndings are also consistent
with the dierential ability of (R)- and (S)-ketamine to produce conditioned place
preference, another model used to predict abuse potential (Yang et al. 2015).
Taken as a whole, the present data indicate that racemic ketamine produces more
severe cognitive impairment than its enantiomers although the nature of these cog-
nitive, motor, and/or motivational dierences need detailed experimental scrutiny. In
addition, we report that racemic ketamine and its isomers share overlapping but not
isomorphic discriminative stimulus eects in rats. The present set of experiments is
the rst to report data on cognition testing with the ketamine isomers in rats and in
rats trained to discriminate the isomers of ketamine. Additional work is needed to fully
understand the mechanisms underlying the discriminative control produced by these
isomers (e.g., which NMDA ion-channel blockers might dierentially substitute, and
which non-NMDA receptor-linked compounds might dierentially substitute for each
isomeric drug form). At present, the data predict a distinct subjective response of (R)-
vs. (S)-ketamine in humans as has been already hinted at by literature reports.
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